- Home
- SEPN vs TYRA Comparison
SEPN vs TYRA Comparison
Compare SEPN & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEPN
- TYRA
- Stock Information
- Founded
- SEPN 2022
- TYRA 2018
- Country
- SEPN United States
- TYRA United States
- Employees
- SEPN N/A
- TYRA N/A
- Industry
- SEPN
- TYRA Biotechnology: Pharmaceutical Preparations
- Sector
- SEPN
- TYRA Health Care
- Exchange
- SEPN NYSE
- TYRA Nasdaq
- Market Cap
- SEPN 631.0M
- TYRA 666.4M
- IPO Year
- SEPN 2024
- TYRA 2021
- Fundamental
- Price
- SEPN $5.80
- TYRA $13.17
- Analyst Decision
- SEPN Buy
- TYRA Strong Buy
- Analyst Count
- SEPN 4
- TYRA 6
- Target Price
- SEPN $34.00
- TYRA $30.50
- AVG Volume (30 Days)
- SEPN 857.5K
- TYRA 254.2K
- Earning Date
- SEPN 02-28-2025
- TYRA 03-18-2025
- Dividend Yield
- SEPN N/A
- TYRA N/A
- EPS Growth
- SEPN N/A
- TYRA N/A
- EPS
- SEPN N/A
- TYRA N/A
- Revenue
- SEPN $981,000.00
- TYRA N/A
- Revenue This Year
- SEPN $406.62
- TYRA N/A
- Revenue Next Year
- SEPN N/A
- TYRA N/A
- P/E Ratio
- SEPN N/A
- TYRA N/A
- Revenue Growth
- SEPN N/A
- TYRA N/A
- 52 Week Low
- SEPN $4.17
- TYRA $11.89
- 52 Week High
- SEPN $28.99
- TYRA $29.60
- Technical
- Relative Strength Index (RSI)
- SEPN N/A
- TYRA 43.64
- Support Level
- SEPN N/A
- TYRA $12.27
- Resistance Level
- SEPN N/A
- TYRA $13.79
- Average True Range (ATR)
- SEPN 0.00
- TYRA 0.71
- MACD
- SEPN 0.00
- TYRA 0.03
- Stochastic Oscillator
- SEPN 0.00
- TYRA 51.09
About SEPN SEPTERNA INC
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, and GLP-1R, GIPR, GCGR.
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).